AmerisourceBergen Announces Date and Time for Third Quarter Fiscal 2017 Earnings Release
July 06 2017 - 6:30AM
Business Wire
AmerisourceBergen Corporation (NYSE: ABC) today announced that
it plans to release its results for the Third Quarter Fiscal 2017
on Thursday, August 3, 2017 prior to the opening of trading on the
New York Stock Exchange. The Company will host a conference call to
discuss the results at 8:30 a.m. ET on August 3, 2017.
Participating in the conference call will be:
Steven H. Collis, Chairman, President &
Chief Executive OfficerTim G. Guttman, Executive Vice President
& Chief Financial Officer
The dial-in number for the live call will be (612) 288-0340. No
access code is required. The live call will also be webcast via the
Company’s website at www.amerisourcebergen.com. Users are
encouraged to log on to the webcast approximately 10 minutes in
advance of the scheduled start time of the call.
Replays of the call will be made available via telephone and
webcast. A replay of the webcast will be posted on
www.amerisourcebergen.com approximately two hours after the
completion of the call and will remain available for 30 days. The
telephone replay will also be available approximately two hours
after the completion of the call and will remain available for
seven days. To access the telephone replay from within the U.S.,
dial (800) 475-6701. From outside the U.S., dial (320) 365-3844.
The access code for the replay is 426711.
About AmerisourceBergen
AmerisourceBergen provides pharmaceutical products,
value-driving services and business solutions that improve access
to care. Tens of thousands of healthcare providers, veterinary
practices and livestock producers trust us as their partner in the
pharmaceutical supply chain. Global manufacturers depend on us for
services that drive commercial success for their products. Through
our daily work—and powered by our 19,000 associates—we are united
in our responsibility to create healthier futures.
AmerisourceBergen is ranked #11 on the Fortune 500, with more than
$145 billion in annual revenue. The company is headquartered in
Valley Forge, Pa. and has a presence in 50+ countries. Learn more
at amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking
Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Words such as "expect," "likely," "outlook,"
"forecast," "would," "could," "should," "can," "will," "project,"
"intend," "plan," "continue," "sustain," "synergy," "on track,"
"believe," "seek," "estimate," "anticipate," "may," "possible,"
"assume," variations of such words, and similar expressions are
intended to identify such forward-looking statements. These
statements are based on management's current expectations and are
subject to uncertainty and change in circumstances. These
statements are not guarantees of future performance and are based
on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated. Among the factors
that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: unfavorable
trends in brand and generic pharmaceutical pricing, including in
rate or frequency of price inflation or deflation; competition and
industry consolidation of both customers and suppliers resulting in
increasing pressure to reduce prices for our products and services;
changes in pharmaceutical market growth rates; substantial defaults
in payment, material reduction in purchases by or the loss,
bankruptcy or insolvency of a major customer; changes to the
customer or supplier mix; the retention of key customer or supplier
relationships under less favorable economics or the adverse
resolution of any contract or other dispute with customers or
suppliers; changes to customer or supplier payment terms; the
disruption of AmerisourceBergen's cash flow and ability
to return value to its stockholders in accordance with its past
practices; risks associated with the strategic, long-term
relationship between Walgreens Boots Alliance,
Inc. and AmerisourceBergen, including with respect to the
pharmaceutical distribution agreement and/or the global sourcing
arrangement; changes in the United States healthcare and
regulatory environment, including changes that could impact
prescription drug reimbursement
under Medicare and Medicaid; increasing governmental
regulations regarding the pharmaceutical supply channel and
pharmaceutical compounding; federal and state government
enforcement initiatives to detect and prevent suspicious orders of
controlled substances and the diversion of controlled substances;
federal and state prosecution of alleged violations of related laws
and regulations, and any related litigation, including shareholder
derivative lawsuits or other disputes relating to our distribution
of controlled substances; increased federal scrutiny and qui tam
litigation for alleged violations of fraud and abuse laws and
regulations and/or any other laws and regulations governing the
marketing, sale, purchase and/or dispensing of pharmaceutical
products or services and any related litigation; material adverse
resolution of pending legal proceedings; declining reimbursement
rates for pharmaceuticals; the acquisition of businesses that do
not perform as expected, or that are difficult to integrate or
control, including the integration of PharMEDium, or the inability
to capture all of the anticipated synergies related thereto;
regulatory action in connection with the production, labeling or
packaging of products compounded by our compounded sterile
preparations (CSP) business; declining economic conditions
in the United States and abroad; financial market
volatility and disruption; the loss, bankruptcy or insolvency of a
major supplier; interest rate and foreign currency exchange rate
fluctuations; managing foreign expansion, including non-compliance
with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and
economic sanctions and import laws and regulations; malfunction,
failure or breach of sophisticated information systems to operate
as designed; risks generally associated with data privacy
regulation and the international transfer of personal data; changes
in tax laws or legislative initiatives that could adversely
affect AmerisourceBergen's tax positions and/or
AmerisourceBergen’s tax liabilities or adverse resolution of
challenges to AmerisourceBergen's tax positions; natural
disasters or other unexpected events that
affect AmerisourceBergen's operations; the impairment of
goodwill or other intangible assets, resulting in a charge to
earnings; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors
affecting AmerisourceBergen's business generally. Certain
additional factors that management believes could cause actual
outcomes and results to differ materially from those described in
forward-looking statements are set forth (i) in Item 1A (Risk
Factors) in the Company’s Annual Report on Form 10-K for the fiscal
year ended September 30, 2016 and elsewhere in that
report and (ii) in other reports filed by the Company pursuant to
the Securities Exchange Act.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170706005206/en/
AmerisourceBergen CorporationKeri P. Mattox,
610-576-7801Vice President, Corporate & Investor
Relationskmattox@amerisourcebergen.comorBennett
S. Murphy, 610-727-3693Director, Corporate & Investor
Relationsbmurphy@amerisourcebergen.com
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024